Oregon woman develops rare blood clot, dies after receiving Johnson & Johnson COVID-19 vaccine

Becky1951

Becky1951

🌹
Location
Tennessee
Health officials stress they cannot say until investigation is complete whether death related to shot

BEND, Ore. (KTVZ) -- An Oregon woman has died after receiving the Johnson & Johnson COVID-19 vaccine, officials with the Oregon Health Authority announced Thursday. The federal Centers for Disease Control and Prevention is now investigating the death, to find out if it was in fact related to the vaccine.


The announcement came just one day before the CDC is reportedly leaning toward lifting the pause on the nationwide distribution of the vaccine, which has been in place since April 13. It went into effect after reports of rare blood clots found in six women after they received the Johnson & Johnson COVID-19 vaccine.

The Oregon woman is the seventh to be hospitalized because of blood clots after receiving the vaccine, and the second to die.

Despite Thursday's announcement, OHA Senior Health Advisor Dr. Shimi Sharief said the state agency will follow the CDC in its recommendation on whether or not to resume distribution of the vaccine.

"If the CDC does make a recommendation to resume distribution of Johnson and Johnson vaccine, we have the utmost confidence that it will be a decision made with thorough investigation and consideration of the potential benefits and risks in relationship to each other as we go through this pandemic," she said in a media briefing late Thursday. "In that sense, we would reflect our distribution process based on the recommendation of the ACIP tomorrow."

Here's the full news release sent out by the Oregon Health Authority:

The Oregon Health Authority said Thursday it's been informed the Centers for Disease Control and Prevention is investigating the death of an Oregon woman this week who developed a rare blood clot following immunization with Johnson & Johnson’s COVID-19 vaccine.

Information about the death has been sent to the CDC through the Vaccine Adverse Event Reporting System (VAERS), the national reporting system used to collect reports of adverse events after vaccination.

OHA was notified of the potential adverse event on Tuesday, two days after the CDC was notified. The Oregon resident, a woman in her 50s, received a dose of the Johnson & Johnson COVID-19 vaccine before the pause order on its use was issued. OHA has not identified where in Oregon the woman resided.

"Until the investigation is complete, it cannot be concluded whether her death is related to the vaccine," OHA said in its announcement.

Officials said the woman developed a rare but serious blood clot within two weeks following vaccination. The blood clot was seen in combination with very low platelets. Prior to the issuance of the pause, cases of this serious blood clot had been identified among six women around the country who received the vaccine.

Health care providers are required to report certain adverse events after COVID-19 vaccines, in accordance with the emergency use authorization (EUA) for COVID-19 vaccines. These include serious adverse events, such as death, any life-threatening event and inpatient hospitalization. At the time of the CDC–FDA pause recommendation, about 7.5 million doses of the Johnson & Johnson vaccine had been administered in the United States, with more than 87,000 doses having been administered at locations throughout Oregon.

"The case in Oregon will add to the evidence of potential risk associated with Johnson & Johnson vaccine," OHA said. The Advisory Committee on Immunization Practices will review the data accumulated to date and weigh the risks and benefits of the vaccine. These considerations will inform the ACIP’s recommendations regarding use of the vaccine going forward.

The CDC and OHA will provide updates on any developments as they can be shared during the review and investigation process.

"OHA still continues to encourage all Oregonians to schedule an appointment to receive a COVID-19 vaccination when appointments become available," the agency said.

https://ktvz.com/news/coronavirus/2...r-receiving-johnson-johnson-covid-19-vaccine/
 

They always use the word "Rare." It's too soon to know how rare it is. And not all complications will be noted; it's not that simple with medical issues.
 
It's interesting that this side-effect is happening with all the vaccines. There must be an ingredient common to them all....so hopefully that will be isolated and replaced.
 

Rosemarie said:
It's interesting that this side-effect is happening with all the vaccines. There must be an ingredient common to them all....so hopefully that will be isolated and replaced.
Click to expand...
The last I read about this, they had it mostly figured out that vaccines can sometimes trigger a rare pre-existing condition in people. I should have paid more attention.
 
Now that these sad death are being reported more
often, is there any word if the unlucky individuals are
healthy people?

Mike.
 
Mike said:
Now that these sad death are being reported more
often, is there any word if the unlucky individuals are
healthy people?
Click to expand...
My son was
Died a few days after getting his vaccine


win231 said:
They always use the word "Rare." It's too soon to know how rare it is. And not all complications will be noted; it's not that simple with medical issues.
Click to expand...
My lady got on a victims and families vaccine site
Her post about our son garnered thousands of hits within a couple hours
And she could not keep up with the replies
 
Sunny said:
Becky gives the case of SIX women getting a rare type of blood clot. Six out of umpteen millions sounds pretty "rare" to me.
Click to expand...
More then just 6 and not just J&J vaccine.

Studies suggest link between blood clots, AstraZeneca COVID vaccine​

Two studies today in the New England Journal of Medicine describe 11 patients in Austria and Germany and 5 in Norway who developed an unusual blood clotting disorder after receiving their first dose of the AstraZeneca/Oxford COVID-19 vaccine.

Clots form in brain, abdomen​

The first study, led by researchers at the Institute for Immunology and Transfusion Medicine in Greifswald, Germany, involved 11 patients who had abnormal blood clots or thrombocytopenia (low platelet counts) 5 to 16 days after receiving the AstraZeneca vaccine.

One patient had a fatal intracranial hemorrhage (bleeding in the brain), while nine had cerebral venous thrombosis (blood clots in the brain), three had splanchnic vein thrombosis (blood clots in abdominal veins), three had a pulmonary embolism (blockage in a lung artery caused by blood clots), and four had other types of blood clots. Six patients, in addition to the patient with fatal intracranial hemorrhage, died.

Five patients had disseminated intravascular coagulation, a condition in which blood clots form in different parts of the body and block small blood vessels. No patients had received heparin to prevent blood clots before their symptoms began.

Twenty-eight patients from another sample referred for investigation of vaccine-induced abnormal blood clotting tested positive for heparin-induced platelet factor 4 (PF4) thrombocytopenia antibodies, independent of heparin. All of them also tested positive for platelet-activating antibodies.

Platelets are involved in the blood clotting process. The study authors said high levels of heparin, Fc receptor-blocking monoclonal antibody, and immunoglobulin inhibited platelet activation.

Nine of the 11 patients were women, and the median patient age was 36 years (range, 22 to 49).

Non-heparin blood thinners​

The authors noted that 82 million doses of COVID-19 vaccines had been administered in Europe by Apr 7, with a quarter of all vaccinees in Germany and 30% in Austria receiving the AstraZeneca vaccine. Reports of vaccine-induced blood clots began to surface in late February.

The post-vaccine abnormal blood clotting disorder, which resembles one induced by heparin, has been reported in patients not given heparin but taking certain drugs or having viral and bacterial infections. This condition has been termed autoimmune heparin-induced thrombocytopenia, the authors said.

"Unlike patients with classic heparin-induced thrombocytopenia, patients with autoimmune heparin-induced thrombocytopenia have unusually severe thrombocytopenia, an increased frequency of disseminated intravascular coagulation, and atypical thrombotic events," the researchers wrote. "Serum from these patients strongly activate platelets in the presence of heparin…but also in the absence of heparin (heparin-independent platelet activation)."

The researchers said that healthcare providers should be alert for venous or arterial blood clots in unusual sites such as the abdomen or brain in patients 5 to 20 days after receiving the AstraZeneca vaccine.

"Given the parallels with autoimmune heparin-induced thrombocytopenia, anticoagulant options should include nonheparin anticoagulants used for the management of heparin-induced thrombocytopenia, unless a functional test has excluded heparin-dependent enhancement of platelet activation," the authors concluded.

"Finally, we suggest naming this novel entity vaccine-induced immune thrombotic thrombocytopenia (VITT) to avoid confusion with heparin-induced thrombocytopenia."

A 'rare vaccine-related variant'​

In the second study, researchers in Norway report on five healthcare workers with venous blood clots in unusual sites and severe thrombocytopenia 7 to 10 days after their first dose of the AstraZeneca vaccine. The workers, who were 32 to 54 years old, also had high concentrations of PF4 antibodies but had not received heparin.

Four patients had cerebral venous thrombosis with intracranial hemorrhage, and three died.

All patients had high levels of D-dimer, indicating blood clots. High-dose heparin was given to four patients, successfully inhibiting blood clots in two of them but less efficiently in the other two. The fifth patient received no heparin.

"Collectively, these results suggest that the serum in these patients contained immune complexes with a mixture of antibody specificities similar to those described in the serum of patients with autoimmune heparin-induced thrombocytopenia," the researchers said. "By providing a link between thrombosis and the immune system, these results strengthen the view that vaccination may have triggered the syndrome."

In Norway, as of Mar 20, when AstraZeneca vaccination was paused, 132,686 healthcare workers and nursing home residents had received one dose. No one had received the second dose.

"Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia," the authors wrote. "Although rare, VITT is a new phenomenon with devastating effects for otherwise healthy young adults and requires a thorough risk–benefit analysis."

https://www.cidrap.umn.edu/news-per...between-blood-clots-astrazeneca-covid-vaccine
 

You must log in or register to reply here.

Back
Top